Processa Pharmaceuticals Stock Analysis
PCSA Stock | USD 0.25 0.03 13.36% |
Processa Pharmaceuticals is undervalued with Real Value of 1.66 and Target Price of 6.0. The main objective of Processa Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Processa Pharmaceuticals is worth, separate from its market price. There are two main types of Processa Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Processa Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Processa Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Processa Stock Analysis Notes
The company has price-to-book ratio of 1.58. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Processa Pharmaceuticals recorded a loss per share of 3.06. The entity last dividend was issued on the 23rd of December 2019. The firm had 1:20 split on the 22nd of January 2024. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. To find out more about Processa Pharmaceuticals contact the company at 443 776 3133 or learn more at https://www.processapharmaceuticals.com.Processa Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Processa Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Processa Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Processa Pharmaceuticals had very high historical volatility over the last 90 days | |
Processa Pharmaceuticals has some characteristics of a very speculative penny stock | |
Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Processa Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: What drives Processa Pharmaceuticals Inc. stock price - Rapid wealth accumulation - Autocar Professional |
Processa Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Processa Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Processa Largest EPS Surprises
Earnings surprises can significantly impact Processa Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2022-03-30 | 2021-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2023-03-30 | 2022-12-31 | -0.32 | -0.36 | -0.04 | 12 |
Processa Stock Institutional Investors
Shares | Absolute Investment Management Llc | 2024-12-31 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 56 K | Virtu Financial Llc | 2025-03-31 | 43.2 K | Geode Capital Management, Llc | 2025-03-31 | 34.4 K | Vanguard Group Inc | 2025-03-31 | 24.4 K | Miracle Mile Advisors, Inc. | 2025-03-31 | 10 K | Tower Research Capital Llc | 2025-03-31 | 2.5 K | Wells Fargo & Co | 2025-03-31 | 154 | Ubs Group Ag | 2025-03-31 | 56.0 | Bank Of America Corp | 2025-03-31 | 37.0 |
Processa Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.88 M.Processa Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (3.67) | (3.85) | |
Return On Capital Employed | (7.10) | (6.75) | |
Return On Assets | (3.67) | (3.85) | |
Return On Equity | (6.99) | (6.64) |
Management Efficiency
Processa Pharmaceuticals has return on total asset (ROA) of (1.0242) % which means that it has lost $1.0242 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9272) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of July 22, 2025, Return On Tangible Assets is expected to decline to -3.85. The current year's Return On Capital Employed is expected to grow to -6.75. At present, Processa Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Total Assets are forecasted to decline to about 3.1 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.55 | 0.53 | |
Tangible Book Value Per Share | 0.55 | 0.58 | |
Enterprise Value Over EBITDA | (0.13) | (0.14) | |
Price Book Value Ratio | 1.59 | 1.51 | |
Enterprise Value Multiple | (0.13) | (0.14) | |
Price Fair Value | 1.59 | 1.51 | |
Enterprise Value | 1.8 M | 1.7 M |
Leadership at Processa Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 22nd of July, Processa Pharmaceuticals holds the Semi Deviation of 7.5, risk adjusted performance of 0.0171, and Coefficient Of Variation of 11386.48. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Processa Pharmaceuticals, as well as the relationship between them.Processa Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Processa Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Processa Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Processa Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Processa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Processa Pharmaceuticals Outstanding Bonds
Processa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Processa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Processa bonds can be classified according to their maturity, which is the date when Processa Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
PROCTER GAMBLE 645 Corp BondUS742718BH18 | View | |
US742718AV11 Corp BondUS742718AV11 | View | |
PROCTER GAMBLE 55 Corp BondUS742718CB39 | View | |
PROCTER GAMBLE 555 Corp BondUS742718DF34 | View | |
PROCTER GAMBLE 58 Corp BondUS742718DB20 | View | |
PROCTER GAMBLE 245 Corp BondUS742718ER62 | View | |
PROCTER GAMBLE 27 Corp BondUS742718EP07 | View | |
PROCTER GAMBLE 285 Corp BondUS742718EV74 | View |
Processa Pharmaceuticals Predictive Daily Indicators
Processa Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Processa Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Processa Pharmaceuticals Forecast Models
Processa Pharmaceuticals' time-series forecasting models are one of many Processa Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Processa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Processa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Processa Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Processa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Processa Pharmaceuticals. By using and applying Processa Stock analysis, traders can create a robust methodology for identifying Processa entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (77.55) | (73.67) | |
Operating Profit Margin | (441.95) | (419.85) | |
Net Loss | (77.28) | (73.41) | |
Gross Profit Margin | 0.65 | 0.68 |
Current Processa Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Processa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Processa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.0 | Hold | 1 | Odds |
Most Processa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Processa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Processa Pharmaceuticals, talking to its executives and customers, or listening to Processa conference calls.
Processa Stock Analysis Indicators
Processa Pharmaceuticals stock analysis indicators help investors evaluate how Processa Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Processa Pharmaceuticals shares will generate the highest return on investment. By understating and applying Processa Pharmaceuticals stock analysis, traders can identify Processa Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 4.7 M | |
Common Stock Shares Outstanding | 3.1 M | |
Total Stockholder Equity | 1.7 M | |
Total Cashflows From Investing Activities | -3244.00 | |
Property Plant And Equipment Net | 75.7 K | |
Cash And Short Term Investments | 1.2 M | |
Cash | 1.2 M | |
Accounts Payable | 880.9 K | |
Net Debt | -1.1 M | |
50 Day M A | 0.2552 | |
Total Current Liabilities | 1.5 M | |
Non Current Assets Total | 1.3 M | |
Non Currrent Assets Other | 1.2 M | |
Stock Based Compensation | 629.5 K |
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |